A Phase II Trial Of Irinotecan /5-FU/ Leucovorin Or Oxaliplatin /5-FU / Leucovorin With And Without Cetuximab (C225) For Patients With Untreated Metastatic Adenocarcinoma Of The Colon or Rectum

NCT00077233 Phase 3 TERMINATED

This is a randomized phase II study trial that has served as a screening trial to test the increased efficacy of chemotherapy + cetuximab versus chemotherapy alone among patients with untreated, advanced or metastatic colon cancer regardless of tumor status with respect to EGFR.

Details

Lead sponsor	Alliance for Clinical Trials in Oncology
Phase	Phase 3
Status	TERMINATED
Enrolment	238
Start date	2003-12
Completion	2010-06

Conditions

• Colorectal Cancer

Interventions

• cetuximab
• 5-FU
• irinotecan
• leucovorin
• oxaliplatin

Primary outcomes

• Overall survival — Up to 3 years of follow up

Countries

United States